In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633

CHF5633 surfactant dose-finding study

Francesca Ricci¹, Xabier Murgia², Roberta Razzetti¹, Nicola Pelizzi¹, Fabrizio Salomone¹.

¹R&D Department, Chiesi Farmaceutici, Parma, Italy.

²Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland, Saarbrücken, Germany.

Corresponding author:

Fabrizio Salomone, PhD. Largo Francesco Belloli, 11/A 43122, Parma, ITALY; Tel. +39 0521 1689158. E-mail. f.salomone@chiesi.com

Statement of financial support

Francesca Ricci, Nicola Pelizzi and Fabrizio Salomone are Chiesi Farmaceutici employees. Roberta Razzetti is a former Chiesi Farmaceutici employee now retired. Xabier Murgia is a Chiesi Farmaceutici preclinical consultant. Chiesi Farmaceutici supplied all the material and specifically its own products (Poractant Alfa and CHF5633) and it fully funded the study.

Statement of financial ties to product

There are no further disclosures.

Category of study

Translational research

ABSTRACT

Background: CHF5633 is a new generation synthetic surfactant containing both SP-B and SP-C analogues developed for the treatment of respiratory distress syndrome. Here the optimal dose and its performance in comparison to the animal-derived surfactant poractant alfa were investigated.

Methods: *in vitro* surfactant activity was determined by means of the Wilhelmy balance and the capillary surfactometer. The dose-finding study was performed in preterm rabbits with severe surfactant deficiency. CHF5633 doses ranging from 50 to 300 mg/kg were used. Untreated animals and animals treated with 200 mg/kg of poractant alfa were included for comparison.

Results: *in vitro*, minimum surface tension ($\gamma_{\min}$) was decreased from values above 70 mN/m to 0 mN/m by both surfactants, and they formed rapidly a film at the air-liquid interface. *In vivo* studies showed a clear dose-dependent improvement of lung function for CHF5633. The pulmonary effect of CHF5633 200 mg/kg dose was comparable to the pulmonary response elicited by 200 mg/kg of poractant alfa in preterm rabbits.

Conclusions: CHF5633 is as efficient as poractant alfa in our *in vitro* and *in vivo* settings. A clear dose-dependent improvement of lung function could be observed for CHF5633, with the dose of 200 mg/kg being the most efficient one.

INTRODUCTION

Respiratory Distress Syndrome (RDS) is a condition of pulmonary insufficiency caused by a primary deficiency of alveolar surfactant. The lack of surfactant results in a high intra-alveolar surface tension that leads to alveolar collapse. Preterm neonates developing RDS have very low intrapulmonary surfactant pool(1-4) several folds lower than the pool size estimated for term neonates(5). Surfactant replacement therapy, which consists on instilling a dose of exogenous surfactant intratracheally, improves rapidly the overall lung function and reduces the mortality and the morbidity associated with RDS(6).

At the early development stages of the therapy, synthetic surfactants containing exclusively phospholipids were formulated(7, 8). Further research clearly showed that the dynamic properties of DPPC alone are suboptimal(9), and that the presence of the hydrophobic surfactant proteins (SP), SP-B and SP-C, in natural surfactants significantly enhances the surface tension reduction action and provides stability to compressed films (10, 11). Surfactant preparations containing both SP-B and SP-C show a combined effect of surfactant function(12). In fact, animal-derived surfactant preparations, commonly used in clinical practice, contain both SP-B and SP-C(13).

In view of the major role played by SP-B and SP-C for an optimal surfactant function, second generation synthetic surfactants incorporated peptides that would further mimic the action of SP-B and SP-C(14). The rationale to develop synthetic surfactants has traditionally relied on the potential of improving the quality control of surfactant, reducing batch-to-batch variability, and avoiding the need of animal reservoir. Moreover, a very interesting feature of peptide-containing synthetic surfactants is their potential to resist inhibition in the setting of inflammation or edema (very likely to occur in the course of RDS) to a larger extent than animal-derived preparations(15, 16).

The first peptide-containing synthetic surfactant preparations consisted of phospholipids and a peptide mimic of either SP-B or SPC. *Lucinactant* is an SP-B-based synthetic surfactant composed of a phospholipid mixture and *sinapultide*, a leucine- and lysine-rich peptide aimed at mimicking SP-B function(17). *Synsurf* is a surfactant consisting of a phospholipids mixture and two polypeptides: poly-l-lysine electrostatically complexed with poly-l-glutamic acid(18). *Lusupultide* is a mixture of phospholipids supplemented with 2% of human recombinant SP-C(19). These preparations showed promising results in preclinical models of lung disease(20, 21) and some of them were tested in clinical trials(19,22-24). However, increased improvement of lung function by synthetic surfactants containing both SP-B and SP-C analogues, over that with a single surfactant protein, have previously been suggested(25,26).

Chiesi Farmaceutici has developed a new synthetic surfactant, CHF5633, which contains DPPC and POPG (1:1) and incorporates analogues of both SP-B and SP-C, 1.5% of the peptide SP-C analogue and 0.2% of the peptide SP-B analogue, respectively. This composition yielded a drug product with optimal efficacy and stability behavior. Preliminary investigations with CHF5633 in preterm lambs with severe surfactant deficiency have shown superior arterial oxygenation and lung compliance compared to the animal-derived surfactant preparation *beractant*(14). CHF5633 has also shown a higher resistance to albumin inactivation and a lower mortality rate in ventilated preterm lambs, compared to the natural surfactant *poractant alfa*(16). In these studies CHF5633 was administered at a dose of 200 mg/kg, emulating *poractant alfa* approved dosage, even if the two surfactants differ in phospholipid composition and contain SP with different length and amino acid composition.

In the present study our aim was to determine the optimal dosage regimen for CHF5633. We conducted an *in vivo* dose-response study in a rabbit neonatal RDS model with a severe primary

surfactant deficiency(27,28).Additionally, we also compared the performance, *in vitro* and *in vivo*, of CHF5633 to the well-tested and highly effective animal-derived surfactant *poractant alfa*.

RESULTS

In vitro surfactant activity: Wilhelmy Balance

Surface tension measurements with the Wilhelmy balance clearly demonstrated that poractant alfa and CHF5633 were very effective in reducing surface tension, compared to saline. Minimum surface tension ($\gamma_{\min}$) was decreased from values above 70 mN/m to 0 mN/m by both surfactants (**table 1**). The films formed by CHF5633, however, showed slightly higher maximum surface tension ($\gamma_{\max}$) and surface area values. Both surfactant preparations showed homogeneous results irrespective of the measured batch, indicative of a consistent surfactant performance and reduced batch-to-batch variability.

In vitro surfactant activity: Capillary Surfactometer

Poractant alfa and CHF5633 formed rapidly a film at the air-liquid interface within the capillary lumen so that, the air could continuously flow through the capillary and the pressure within the capillary was maintained near zero for the whole 120 sec recording time. The capillary remained open 99.9% of the 120 sec recording time either poractant alfa or CHF5633. Conversely, in the presence of saline, the airflow was continuously interrupted and capillary patency could be only maintained for less than 10 seconds, accounting for just 3.9% of the recording time. **Figure 1** shows representative recordings for saline (a), poractant alfa (b), CHF5633 and (c); the initial pressures for poractant alfa and CHF5633 were 6.6 and 3.8 cmH₂O, respectively, whereas the initial pressure with saline was 10.5 cmH₂O.

Dose finding of CHF5633 in preterm newborn rabbits

The efficacy of different doses of CHF5633 for RDS treatment was then compared in premature newborn rabbits. The animals from each litter (15 litters in total) were allocated to five or six

experimental groups, depending on the number of fetuses. The animals allocated in the control group received no material (negative control, n=21). A group of animals received a 200 mg/kg dose of poractant alfa intratracheally (positive control, n=20), and four further groups received CHF5633 at doses of 50 (n=23), 100 (n=19), 200 (n=22) and 300 mg/kg (n=18). All surfactant preparations were given at a phospholipid concentration of 80 mg/kg. Sample size, body weight and the mean C_{dyn} , 5 minutes after the initiation of mechanical ventilation are presented in **table 2**. No significant difference was found between groups in terms of bodyweight. Irrespective of the surfactant preparation (poractant alfa or CHF5633) or the dose (range 50-300 mg/kg), surfactant administration significantly improved lung function in comparison to untreated control animals ($p < 0.0001$).

The administration of CHF5633 showed a clear dose-dependent improvement of lung function (**figure 2a**). Five minutes after surfactant administration, the dose of 100 mg/kg of CHF5633 was associated with a significantly higher mean C_{dyn} than with 50 mg/kg ($p < 0.01$), while lung function after administration of 200 mg/kg of CHF5633 was significantly better than with 100 mg/kg ($p < 0.01$). Further increase of the CHF5633 dose to 300 mg/kg did not produce any significant benefit in lung function, being the mean C_{dyn} values for this dose slightly but not significantly lower than with the 200 mg/kg dose. Within the CHF5633 dose-range of 50 to 200 mg/kg, the linear regression analysis showed a positive correlation between the phospholipid concentration and the V_T ($r = 0.791$, $p < 0.01$, **figure 2b**).

Throughout the whole experimental period, no significant differences in terms of V_T were observed between CHF5633 doses of 200 and 300 mg/kg and poractant alfa (200 mg/kg), regardless of the positive inspiratory pressure (PIP) level (**figure 3**). At a PIP level of 25 cmH₂O, poractant alfa performed significantly better than CHF5633 50 mg/kg at any point ($p < 0.0001$).

Significant differences of lung function favouring poractant alfa in comparison to CHF5633 administered at 100 mg/kg dose could also be detected 5 and 30 minutes after surfactant administration ($p < 0.01$). At high PIP, both CHF5633 200 and 300 mg/kg groups achieved significantly higher mean V_T than the CHF5633 100 mg/kg group ($p < 0.01$).

Lowering the PIP to 20 cmH₂O (at 20 min) produced a dramatic decrease of the V_T in all surfactant-treated groups. At this time point significant differences between surfactant-treated groups in V_T occurred only between CHF5633 50 mg/kg group and CHF5633 200 mg/kg and poractant alfa groups ($p < 0.01$). Lowering the PIP to 15 cmH₂O decreased the V_T further to the level of the untreated control animals (alveolar collapse).

After restoring the PIP to 25 cmH₂O, at 30 min, the previously observed dose-dependent effect on lung function was again observed among the CHF5633 treated groups. At this time point, no significant differences between poractant alfa, CHF5633 200 mg/kg, and CHF5633 300 mg/kg were observed. However, the mean V_T of these three groups was significantly higher than those observed for CHF5633 100 mg/kg and CHF5633 50 mg/kg.

In vivo comparison between poractant alfa and CHF5633 administered at 200 mg/kg

In order to point out any potential difference in terms of lung mechanics between poractant alfa and CHF5633, the aforementioned experiment was replicated in a number of additional litters with a higher statistical power comparing the most effective CHF5633 dose (200 mg/kg) to a 200 mg/kg dose of poractant alfa, a dose indicated for the clinical treatment of RDS. In this new set of experiments, the animals from each litter (16 new litters in total) were allocated to one of the three experimental groups: 1) Control group, which received no material (n=38), 2) poractant alfa group, which received 200 mg/kg of poractant alfa intratracheally (n=52), or 3) CHF5633 group,

which received 200 mg/kg of CHF5633 intratracheally (n=53). Sample size, Body weight, and dynamic compliance values at 5 min (PIP 25 cmH₂O), 25 min (PIP 15 cmH₂O), and 30 min (PIP 25 cmH₂O) are shown in **table 3**. No significant differences between groups were found for the body weight. Compared to untreated control animals, both surfactant preparations significantly improved C_{dyn} already 5 minutes after surfactant treatment ($p < 0.0001$). C_{dyn} dropped in all groups as a consequence of turning the PIP down from 25 to 15 cmH₂O. C_{dyn} values with the PIP set at 15 cmH₂O were virtually the same in both surfactant-treated groups and significantly higher than those of the control group ($p < 0.01$). After restoring the PIP to 25 cmH₂O, C_{dyn} values in both surfactant-treated groups rapidly increased to the levels observed 5 min after surfactant administration.

The V_T of animals treated with 200 mg/kg of CHF5633 or poractant alfa were significantly higher compared to untreated control animals (**figure 4**). The V_T of the CHF5633 200 mg/kg group remained stable for the first 15 min after surfactant administration, whereas in the poractant alfa group, V_T gradually decreased in the same time period compared to the initial recorded value. This decrease in the poractant alfa group accounted for a marginal significant difference between surfactant-treated groups, 10 and 15 min after the initiation of mechanical ventilation ($p < 0.05$).

Surfactant-treated animals had a significantly higher fraction of survivors ($p < 0.01$) in comparison to untreated controls (**figure 5**).

DISCUSSION

CHF5633 is the first synthetic surfactant in clinical development that includes, in addition to phospholipids, both SP-B and SP-C analogues. In the present study, we investigated the performance, *in vitro* and *in vivo*, of the synthetic surfactant CHF5633 and we compared it to the highly-effective clinically available animal-derived surfactant poractant alfa. In particular, we conducted a dose-finding study for CHF5633 in preterm rabbits with severe RDS to identify its optimal therapeutic dose.

In the first place, we compared the performance of CHF5633 and poractant alfa *in vitro*. The critical characteristics of a surfactant preparation intended for treatment of RDS are the efficiency to spread rapidly over the alveolar surface, and the ability to reduce the surface tension to values close to 0 mN/m upon compression, in order to avoid the alveolar collapse at the end of the expiratory phase. In this regard, both surfactant preparations formed rapidly a film at the air-liquid interface as determined by the Capillary Surfactometer, indicative of a rapid spreading of the surfactant films. Moreover, cycling compression with the Wilhelmy Balance yielded minimum surface tension ($\gamma_{\min}$) values of 0 mN/m for both surfactant preparations, suggesting that both preparations may perform good even in the absence of positive end-expiratory pressure (PEEP). Poractant alfa films were characterized by a lower maximum surface tension ($\gamma_{\max}$) and a bigger surface area than CHF5633. Nonetheless, the *in vitro* requirements for a “good” pulmonary surfactant were met by CHF5633.

The *in vivo* dose-finding study with CHF5633 showed a clear dose-dependent improvement of lung function. The dose-range for this study was selected based in the dose-response study performed by Bongrani *et al.* for poractant alfa(29). The linear regression analysis revealed a positive linear correlation between the phospholipid concentration and the improvement of the

respiratory parameters in the dose range between 50 and 200 mg/kg. Interestingly, even the lowest CHF5633 dose (50 mg/kg) administered to preterm rabbits elicited a significant improvement of lung function. Dose-dependent improvements of lung function have been described for animal-derived surfactant preparations, including, bovactant (Alveofact, Boehringer)(30), surfactant TA (Surfacten, Tokyo-Tanabe Co)(31), and poractant alfa(29). For the latter, dose-dependent improvements were noted up to a dose of 300 mg/kg(29). In the present study, a further increase of the CHF5633 dose to 300 mg/kg was of no further benefit, and was associated with a slightly lower pulmonary response than the 200 mg/kg dose, probably due to the excessive surfactant volume that had to be intratracheally instilled (3.75 ml/kg of CHF5633 to animals with an initial mean tidal volume of 1.5 ml/kg). However, it should be noted that 200 and 300 mg/kg doses of CHF5633 showed an equivalent pulmonary response as the animal-derived surfactant poractant alfa, administered at 200 mg/kg.

In the applied ventilation protocol, the PIP was stepwise turned down from 25 cmH₂O (0-15 min) to 15 cmH₂O (at 25 min), a fact that induced a dramatic decrease of C_{dyn}, and a drop of V_T in all groups (alveolar collapse). As soon as the pressure was again restored to 25 cmH₂O, all surfactant-treated groups, irrespective of the dose or the surfactant preparation, returned to the “pre-collapse” C_{dyn} and V_T values, which (in addition to the fact that no PEEP was used during the ventilation protocol) highlights the good *in vivo* efficacy of the novel synthetic surfactant CHF5633.

The CHF5633 dose of 200 mg/kg showed the highest efficacy. In order to identify any potential difference in performance between the synthetic and the animal-derived surfactants administered at 200 mg/kg, a new set of *in vivo* experiments with a higher statistical power (n = 52, poractant alfa; n = 53, CHF5633) was designed. During the first 15 min of mechanical ventilation there was

a downwards trend on V_T in the poractant alfa group, while V_T remained constant in the CHF5633 group. This difference in the V_T pattern resulted in transient significant differences between groups at 10 and 15 min. A similar downward trend after poractant alfa administration was also reported by Bongrani *et al.* in the same preterm animal model(29). The reason for this slight decrease of V_T is unknown but is not associated to ventilation management since ventilation settings remained unchanged for the initial 15 min of mechanical ventilation. It could be speculated that soon after the initiation of mechanical ventilation with a high PIP alveolar permeability might increase and the inflammatory cascade might be initiated, resulting in the inactivation of a fraction of the administered animal-derived surfactant by intra-alveolar proteins or inflammatory mediators; this phenomenon might have occurred to a lesser extent for the synthetic surfactant CHF5633(16). It is noteworthy that the treatment of the preterm rabbits with any surfactant preparation significantly increased the fraction of survivors.

In summary, we found a clear dose-dependent improvement within the dose-range of 50 to 200 mg/kg for CHF5633, with the latter dose eliciting the most efficient pulmonary response in preterm rabbits with a severe surfactant deficiency. Furthermore, a comparison between CHF5633 and poractant alfa administered at 200 mg/kg yielded equivalent results. Therefore, the new generation synthetic surfactant CHF5633 at a dose of 200 mg/kg may perform as well as the animal-derived surfactant poractant alfa in preterm neonates with RDS.

MATERIALS AND METHODS

Surfactant preparations

Poractant alfa (Curosurf, Chiesi Farmaceutici, Parma, Italy) is a natural surfactant, prepared from porcine lungs, containing almost exclusively polar lipids, in particular PC (about 70 % of the total phospholipid content), and about 1 % of specific low molecular weight hydrophobic proteins SP-B and SP-C, at a phospholipid concentration of 80 mg/ml.

CHF5633 (Chiesi Farmaceutici, Parma, Italy) is a synthetic surfactant that contains R-dipalmitoylphosphatidylcholine (DPPC) and 1-palmitoyl-2oleoyl-glycero-3-phospho-1-glycerol (POPG) at 1:1 ratio (98.3%), SP-C analogue (1.5%), and SP-B analogue (0.2%), at a phospholipid concentration of 80 mg/ml.

In vitro surfactant activity: Wilhelmy Balance

The surface tension of poractant alfa, CHF5633, and saline solution was measured at 37°C with the Wilhelmy Surface Balance (Biegle, Vienna, Austria). The device uses a platinum plate connected to a strain gauge and inserted 1 mm into the hypophase, consisting of 20 ml of 150 mM NaCl in a teflon through. Surfactant samples (312 µl, at a concentration of 80 mg/ml) or saline were added into the hypophase, 4 cm away from the platinum plate and allowed to spread spontaneously for 3 min. Recordings were then made during cyclic 50% film compression, at a rate of 1/min, for minimum surface tension (γ_{min}) value measurement. Four batches of CHF5633 were tested in parallel with poractant alfa. Saline solution was measured for comparison.

In vitro surfactant activity: Capillary Surfactometer

The ability of CHF5633 and poractant alfa to form a film at the air-liquid interface was evaluated with the Capillary Surfactometer. This instrument simulates the morphology and function of a terminal conducting human airway with a glass capillary that in a short section is particularly narrow. A volume of 0.5 µl of the sample under test (CHF5633, poractant alfa, or saline solution) was deposited in the capillary and a flow of air was applied. The pressure inside the capillary was measured and recorded for 2 min.

Dose finding of CHF5633 in preterm newborn rabbits

Pregnant New Zealand White rabbits (3.4-4.2 kg) were supplied by Charles River (Domaine des Oncins, France) and housed until the 27th day of gestation under standard conditions, according to the current procedures for animal housing and handling. The experimental procedure was approved by the Ethics Committee in animal experiments of Chiesi Farmaceutici and met the standard European regulations on animal research. Management and use of the animals complied with the EEC and national regulations for animal care.

On the 27th day of gestation does were given diazepam (5 mg/kg) and, 10 min later, were anesthetized with ketamine (25 mg/kg). As soon as the anesthesia was effective, the fetuses were delivered by cesarean section, immediately anesthetized with sodium pentobarbital (0.6 mg, i.p.) and tracheotomized, using a stainless steel cannula as tracheal tube (inner diameter: 2 mm). Fetuses, paralyzed with pancuronium bromide (0.06 mg, i.p.), were allocated to each treatment group and submitted to artificial ventilation with 100% oxygen, for 30 min using a servo-ventilator (Siemens 900 C, Erlangen, Germany) according to a fixed ventilation, as previously

described(29). Briefly, fetuses were initially ventilated for 15 min with a PIP of 25 cmH₂O, followed by 5 min at a PIP of 20cmH₂O, another 5 min at a PIP of 15 cmH₂O, and a final step of 5 min in which the PIP was restored at the initial level of 25 cmH₂O. PEEP was not applied during the experiments. Tidal volume (V_T) and dynamic compliance (C_{dyn}) were recorded every 5 minutes with a computerized system (PowerLab, ADI instruments, Dunedin, New Zealand). Electrocardiogram (ECG, BioAmplifier, PowerLab, ADInstruments) was recorded immediately before the initiation of the ventilation and right after the end of the 30 min of experimental time. Animals with a normal P wave/QRS complex were counted as survivors. At the end of ventilation protocol, fetuses were sacrificed with Tanax (0.1 ml intracranial) and their abdomen inspected for pneumothorax (PTX). Animals with evidence of PTX were excluded from the study.

Data analysis

Parametric data are given as Mean $\pm$ Standard Error Mean (SEM). Comparisons between groups for V_T and C_{dyn} were evaluated by Student's t-test with Levene's test for equality of variances (significance level $p < 0.05$). The correlation between the administered dose of CHF5633 and the observed V_T was assessed by linear regression analysis. Fisher's exact test was used to compare survival between groups ($p < 0.01$ was accepted as significant).

REFERENCES

1. Hallman M, Merritt TA, Pohjavuori M, et al. Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure. *Pediatr Res* 1986; 20:1228-35.
2. Jobe A. Metabolism of endogenous surfactant and exogenous surfactants for replacement therapy. *Semin Perinatol* 1988; 12:231-44.
3. Torresin M, Zimmermann LJ, Cogo PE, et al. Exogenous surfactant kinetics in infant respiratory distress syndrome: A novel method with stable isotopes. *Am J Respir Crit Care Med* 2000; 161:1584-9.
4. Carnielli VP, Zimmermann LJ, Hamvas A, et al. Pulmonary surfactant kinetics of the newborn infant: novel insights from studies with stable isotopes. *J Perinatol* 2009; 29 Suppl 2:S29-37.
5. Jobe AH. Pharmacology Review: Why Surfactant Works for Respiratory Distress Syndrome. *NeoReviewsorg* 2006; 7:e95-e106.
6. Engle WA. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. *Pediatrics* 2008; 121:419-32.
7. Robillard E, Alarie Y, Dagenais-Perusse P, et al. Microaerosol Administration of Synthetic Beta-Gamma-Dipalmitoyl-L-Alpha-Lecithin in the Respiratory Distress Syndrome: A Preliminary Report. *Can Med Ass J* 1964; 90:55-7.
8. Chu J, Clements JA, Cotton EK, et al. Neonatal pulmonary ischemia. I. Clinical and physiological studies. *Pediatrics* 1967; 40:Suppl:709-82.
9. Veldhuizen R, Nag K, Orgeig S, et al. The role of lipids in pulmonary surfactant. *Biochim Biophys Acta* 1998; 1408:90-108.

10. Phizackerley PJ, Town MH, Newman GE. Hydrophobic proteins of lamellated osmiophilic bodies isolated from pig lung. *Biochem J* 1979; 183:731-6.
11. Cruz A, Worthman LA, Serrano AG, et al. Microstructure and dynamic surface properties of surfactant protein SP-B/dipalmitoylphosphatidylcholine interfacial films spread from lipid-protein bilayers. *Eur Biophys J* 2000; 29:204-13.
12. Schurch D, Ospina OL, Cruz A, et al. Combined and independent action of proteins SP-B and SP-C in the surface behavior and mechanical stability of pulmonary surfactant films. *Biophys J* 2010; 99:3290-9.
13. Walsh BK, Daigle B, DiBlasi RM, et al. AARC Clinical Practice Guideline. Surfactant replacement therapy: 2013. *Respir Care* 2013; 58:367-75.
14. Sato A, Ikegami M. SP-B and SP-C containing new synthetic surfactant for treatment of extremely immature lamb lung. *PloS One* 2012; 7:e39392.
15. Herting E, Rauprich P, Stichtenoth G, et al. Resistance of different surfactant preparations to inactivation by meconium. *Pediatr Res* 2001; 50:44-9.
16. Seehase M, Collins JJ, Kuypers E, et al. New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs. *PloS One* 2012; 7:e47631.
17. Ma CC, Ma S. The role of surfactant in respiratory distress syndrome. *Open Respir Med J* 2012; 6:44-53.
18. M van Zyl J, Smith J, Hawtrey A. The effect of a peptide-containing synthetic lung surfactant on gas exchange and lung mechanics in a rabbit model of surfactant depletion. *Drug Des Dev Ther* 2013; 7:139-148.
19. Markart P, Ruppert C, Wygrecka M, et al. Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. *Thorax* 2007; 62:588-94.

20. Gastiasoro-Cuesta E, Alvarez-Diaz FJ, Rey-Santano C, et al. Acute and sustained effects of lucinactant versus poractant-alpha on pulmonary gas exchange and mechanics in premature lambs with respiratory distress syndrome. *Pediatrics* 2006; 117:295-303.
21. Ruppert C, Kuchenbuch T, Boensch M, et al. Dry powder aerosolization of a recombinant surfactant protein-C-based surfactant for inhalative treatment of the acutely inflamed lung. *Crit Care Med* 2010; 38:1584-91.
22. Taut FJ, Rippin G, Schenk P, et al. A Search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). *Chest* 2008; 134:724-32.
23. Moya FR, Gadzinowski J, Bancalari E, et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. *Pediatrics* 2005; 115:1018-29.
24. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. *Pediatrics* 2005; 115:1030-8.
25. Almlen A, Walther FJ, Waring AJ, et al. Synthetic surfactant based on analogues of SP-B and SP-C is superior to single-peptide surfactants in ventilated premature rabbits. *Neonatology* 2010; 98:91-99
26. Walther FJ, Hernandez-Juviel JM, Mercado PE, et al. Surfactant with SP-B and SP-C analogues improves lung function in surfactant-deficient rats. *Biol Neonate* 2002; 82:181-187.
27. Lachmann B, Grossmann G, Freyse J, et al. Lung-thorax compliance in the artificially ventilated premature rabbit neonate in relation to variations in inspiration:expiration ratio. *Pediatr Res* 1981; 15:833-838.

28. Almlen A, Stichtenoth G, Robertson B, et al. Concentration dependance of a poly-leucine surfactant protein C analogue on in vitro and in vivo surfactant activity. *Neonatology* 2007; 92:194-200.
29. Bongrani S, Fornasier M, Papotti M, et al. Dose-response study of surfactant replacement in immature newborn rabbits. *Prenat Neonat Med* 1999; 4:71-8.
30. Gortner L, Pohlandt F, Bartmann P, et al. High-dose versus low-dose bovine surfactant treatment in very premature infants. *Acta Paediatr* 1994; 83:135-41.
31. Konishi M, Fujiwara T, Naito T, et al. Surfactant replacement therapy in neonatal respiratory distress syndrome. A multi-centre, randomized clinical trial: comparison of high-versus low-dose of surfactant TA. *Eur J Pediatr* 1988; 147:20-5.

Figure 1. Representative pressure tracings from the capillary surfactometer achieved after testing (a) saline solution, (b) poractant alfa (Curosurf), or (c) CHF5633.

Figure 2. Dynamic compliance after 5 minutes of mechanical ventilation (a) and linear regression analysis ($r^2 = 0.628$) of the tidal volume and the surfactant dose after 15 min of mechanical ventilation (b) in preterm rabbits with severe surfactant deficiency treated with different doses of the synthetic surfactant CHF5633. § p vs. Control (no surfactant) < 0.01 ; * p vs. 50 mg/kg < 0.01 ; ** p vs. 50 mg/kg < 0.0001 ; † p vs. 100 mg/kg < 0.01 ; ‡ p vs. 100 mg/kg < 0.0001 .

Figure 3. Tidal volumes (y-axis) in preterm rabbits with severe surfactant deficiency treated either with different CHF5633 doses (right-pointing solid triangles 50 mg/kg; left-pointing solid triangles 100mg/kg; down-pointing solid triangles 200 mg/kg; and up-pointing solid triangles 300 mg/kg) or with a standard clinical dose of poractant alfa (200 mg/kg, empty squares). Untreated animals managed on mechanical ventilation (empty circles) are shown for comparison. Fetuses were initially ventilated for 15 min with a PIP of 25 cmH₂O, followed by 5 min at a PIP of 20cmH₂O, another 5 min at a PIP of 15 cmH₂O, and a final step of 5 min in which the PIP was restored at the initial level of 25 cmH₂O (x-axis, top). * p vs. CHF5633-200mg/kg < 0.01 ; † p vs. CHF5633-300mg/kg < 0.01 ; § p vs. poractant alfa-200 mg/kg < 0.01 .

Figure 4. Tidal volumes (y-axis) in preterm rabbits with severe surfactant deficiency treated either with CHF5633 (200 mg/kg, solid triangles) or with a standard clinical dose of poractant alfa (200 mg/kg, empty squares). Untreated animals managed on mechanical ventilation (empty circles) are shown for comparison. Fetuses were initially ventilated for 15 min with a PIP of 25 cmH₂O, followed by 5 min at a PIP of 20cmH₂O, another 5 min at a PIP of 15 cmH₂O, and a final step of 5 min in which the PIP was restored at the initial level of 25 cmH₂O (x-axis, top). * p vs. any surfactant treatment < 0.01 ; ** p vs. any surfactant treatment < 0.0001 ; † p vs. poractant alfa-200 mg/kg < 0.05 .

Figure 5. Mosaic plot comparing the survival fractions of CHF5633-treated, poractant alfa-treated, and untreated (control) preterm rabbits. The fraction of survivors corresponds to the solid grey area of each group, whereas the fraction of non-survivors is represented by the white area below. * p vs. Control (no surfactant) < 0.01 . ** p vs. Control < 0.0001 .